Ocuphire Pharma, Inc. (OCUP) ---> Fakten
eröffnet am 08.12.22 11:33:53 von
neuester Beitrag 30.05.24 04:35:46 von
neuester Beitrag 30.05.24 04:35:46 von
Beiträge: 127
ID: 1.365.351
ID: 1.365.351
Aufrufe heute: 0
Gesamt: 10.259
Gesamt: 10.259
Aktive User: 0
ISIN: US67577R1023 · WKN: A2QG4Z · Symbol: OCUP
1,6800
USD
0,00 %
0,0000 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
TitelBeiträge |
---|
10.05.24 · globenewswire |
06.05.24 · globenewswire |
03.05.24 · globenewswire |
22.04.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
3,4800 | +2.018,08 | |
1,5800 | +54,90 | |
24,500 | +22,50 | |
0,7000 | +16,67 | |
2,0400 | +16,50 |
Wertpapier | Kurs | Perf. % |
---|---|---|
160,90 | -14,14 | |
16,100 | -15,26 | |
4,0000 | -20,00 | |
0,7500 | -35,34 | |
2,1000 | -47,50 |
Beitrag zu dieser Diskussion schreiben
F & F
Ocuphire Pharma announced plans to meet with the FDA in the fourth quarter of 2023to advance a phase 3 regulatory path for APX3330, an investigational treatment
for diabetic retinopathy and diabetic macular edema.
Diabetic Retinopathy (DR)/ Macular Edema (DME) https://www.ocuphire.com/product-pipeline/apx3330
May 29, 2024 6:45 am ET
Acquisition includes Restoret™, a novel late-phase candidate for diabetic macular edema
and neovascular age-related macular degeneration, as well as a preclinical pipeline targeting retinal diseases
Restoret anticipated to enter pivotal study for diabetic macular edema in the second half of 2024
Merck to acquire EyeBio for a $1.3 billion upfront payment and up to $1.7 billion
in future milestone payments for a potential value of $3 billion
https://www.merck.com/news/merck-to-acquire-eyebio/
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
https://finance.yahoo.com/news/ocuphire-pharma-announces-fin…
In February 2024, Ocuphire submitted a Special Protocol Assessment (SPA) to the U.S. Food and Drug Administration (FDA)
to seek agreement on the clinical trial protocol and statistical analysis plan for a Phase 2/3 registration study for APX3330 in DR.
Dialogue with the FDA is ongoing, and specifics on the study design and the anticipated timing
will be announced if and when an agreement is reached with the FDA.
https://finance.yahoo.com/news/ocuphire-pharma-announces-fin…
In February 2024, Ocuphire submitted a Special Protocol Assessment (SPA) to the U.S. Food and Drug Administration (FDA)
to seek agreement on the clinical trial protocol and statistical analysis plan for a Phase 2/3 registration study for APX3330 in DR.
Dialogue with the FDA is ongoing, and specifics on the study design and the anticipated timing
will be announced if and when an agreement is reached with the FDA.
“ We are working closely with the FDA
regarding our Special Protocol Assessment
and aim to finalize the Phase 2/3 protocol soon.
We believe that APX3330 has significant potential as a promising oral binocular treatment option for delaying or preventing
DR progression in patients who currently lack effective options prior to developing vision-threatening complications.”
aus der heutigen news https://finance.yahoo.com/news/ocuphire-pharma-announces-pre…
regarding our Special Protocol Assessment
and aim to finalize the Phase 2/3 protocol soon.
We believe that APX3330 has significant potential as a promising oral binocular treatment option for delaying or preventing
DR progression in patients who currently lack effective options prior to developing vision-threatening complications.”
aus der heutigen news https://finance.yahoo.com/news/ocuphire-pharma-announces-pre…
FORM 10-K
As of December 31, 2023, our principal sources of liquidity consisted of cash and cash equivalents of $ 50.5 million
https://app.quotemedia.com/data/downloadFiling?webmasterId=9…
SCHEDULE 14A
https://app.quotemedia.com/data/downloadFiling?webmasterId=9…
Beitrag Nr. 122
der vorherige Beitrag Nr. 122 bezieht sich auf CIDARA 8 & 10
8 K fourth quarter and year endedDecember 31, 2023.
https://app.quotemedia.com/data/downloadFiling?webmasterId=9…
10 K https://app.quotemedia.com/data/downloadFiling?webmasterId=9…
Antwort auf Beitrag Nr.: 75.590.078 von Niller84 am 09.04.24 16:05:26APX3330 Presentation at ARVO 2024 Annual Meeting
Ocuphire’s lead retinal product candidate, APX3330...
...A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have been completed,
and a special protocol assessment (SPA) was submitted to the U.S. Food and Drug Administration (FDA) in February 2024.
https://finance.yahoo.com/news/ocuphire-pharma-announces-apx…
Ocuphire’s lead retinal product candidate, APX3330...
...A Phase 2 study in subjects with DR and an End-of-Phase 2 meeting have been completed,
and a special protocol assessment (SPA) was submitted to the U.S. Food and Drug Administration (FDA) in February 2024.
https://finance.yahoo.com/news/ocuphire-pharma-announces-apx…
Schau mal in die amerikanischen Foren ...
da wird behauptet, dass 300.000 Aktien zum niedrigen Kurs per ATM auf den Markt geworfen wurden. Jetzt will OCUP wohl, dass die Begrenzung auf 20 Prozent der MK aufgehoben wird. Angeblich die Aktien unter Buchwert auf den Markt geworfen. Jussie... behauptet bei stocktwits, dass OCUP ein Übernahmeangebot hatte, dass BOD aber wohl abgelehnt haben soll. Es klingt alles sehr abenteuerlich! Und unfähig. GL
Notice of 2024 Annual Meeting of Stockholders - Date: June 11, 2024
AGENDA PDF seite 3 https://app.quotemedia.com/data/downloadFiling?webmasterId=9…
AGENDA PDF seite 3 https://app.quotemedia.com/data/downloadFiling?webmasterId=9…
ich "hasse" es, wenn ich mit meiner Einschätzung falsch lag
bezüglich der Kursentwicklung UND nicht weiß warum! Nachkaufen mag ich im Augenblick nicht, obwohl es sich wirklich anbieten würde. Warum sind wir in der Position wie OCUP mit einer für mich lächerlichen Marktkatpitalisierung von ca. 42 Millionen USD bewertet mit einem zugelassenen Produkt UND einer Pipeline?Ich verstehe die aktuelle Situation hier nicht! GL
10.05.24 · globenewswire · Ocuphire Pharma |
06.05.24 · globenewswire · Ocuphire Pharma |
03.05.24 · globenewswire · Ocuphire Pharma |
22.04.24 · globenewswire · Ocuphire Pharma |
11.04.24 · globenewswire · Ocuphire Pharma |
01.04.24 · globenewswire · Ocuphire Pharma |
08.03.24 · globenewswire · Ocuphire Pharma |
23.02.24 · globenewswire · Ocuphire Pharma |
15.02.24 · globenewswire · Ocuphire Pharma |
14.02.24 · globenewswire · Ocuphire Pharma |
Zeit | Titel |
---|---|
08.01.24 |